Pantomed (Pantoprazole)

Pantoprazole, the active ingredient in Pantomed, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is employed in the management of acid‑related disorders such as gastro‑esophageal reflux disease, erosive esophagitis, Zollinger‑Ellison syndrome, and prevention of NSAID‑induced gastric ulcers.

GNH USA supplies Pantomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance, and reliable delivery across global markets.

Pantoprazole acts on the gastric proton pump pathway to lower acid production in several acid‑related conditions.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by reducing refluxate acidity. - Erosive esophagitis: promotes healing of mucosal lesions through sustained acid suppression. - Zollinger‑Ellison syndrome: controls hypersecretion of gastric acid caused by gastrin‑producing tumors. - Prevention of NSAID‑induced gastric ulcers: lowers the risk of ulcer formation in patients receiving non‑steroidal anti‑inflammatory drugs.

Adverse reactions may occur with pantoprazole use.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may be self‑limiting. - Nausea: sensation of unease or urge to vomit. - Abdominal pain: discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of swelling, rash, and breathing difficulty. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Low magnesium levels (hypomagnesemia): may cause muscle cramps or cardiac arrhythmia. - Elevated liver enzymes: indicating possible hepatic stress. - Stevens‑Johnson syndrome: rare skin blistering condition. - Interstitial nephritis: inflammation of kidney tissue.

Before initiating therapy, consider the following safety measures.

- Renal function assessment: adjust use in patients with severe renal impairment. - Review concomitant medications: evaluate for potential drug‑drug interactions. - Monitor magnesium levels: especially during prolonged treatment. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Pantoprazole may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect may increase cardiovascular risk. - Atazanavir: decreased absorption leading to sub‑therapeutic antiviral levels. - Methotrexate: increased systemic exposure and potential toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring closer coagulation monitoring. - Digoxin: increased serum concentrations may necessitate dose adjustment. - Fluconazole: may raise pantoprazole levels, warranting observation for side effects.